» Articles » PMID: 36105430

Relationship Between Acyl and Desacyl Ghrelin Levels with Insulin Resistance and Body Fat Mass in Type 2 Diabetes Mellitus

Overview
Publisher Dove Medical Press
Specialty Endocrinology
Date 2022 Sep 15
PMID 36105430
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Although strong evidence suggests that ghrelin plays an important role in regulating energy balance, the effects of acylated ghrelin (AG) and deacylated ghrelin (DAG) on fat mass are largely undefined. This study aimed to investigate the differential associations of both forms of ghrelin with insulin resistance and body fat mass in patients with type 2 diabetes mellitus (T2DM).

Patients And Methods: A total of 162 patients with type 2 diabetes were recruited and classified based on BMI and visceral fat area (VFA) as VFA normal group (n = 78), normal-BMI VFA obesity group (n = 20) and high-BMI VFA obesity group (n = 64). VFA and subcutaneous fat area (SFA) were detected by bioelectrical impedance analysis. Blood samples were collected to measure fasting glucose, insulin, lipids, AG and DAG levels after clinical examination.

Results: Compared with VFA normal group, DAG levels were significantly lower (421.7 ± 106.0 and 388.7 ± 96.5 pg/mL vs 524.4 ± 141.5 pg/mL, P < 0.01) in the two VFA obesity groups. No significant difference was found in AG levels within three groups. Among all subjects, BMI, VFA, SFA, fasting insulin and HOMA-IR were negatively correlated with DAG but positively with AG/DAG ratio (P < 0.01). In contrast, AG was positively correlated with HOMA-IR and fasting glucose (P < 0.01). Multiple stepwise regression analysis showed that fasting glucose was the independent factor of AG, VFA and HOMA-IR were the independent factors related to DAG.

Conclusion: DAG levels have a strong negative association with excess body fat mass and insulin resistance, whereas AG levels are closely related to elevated blood glucose levels in T2DM patients.

Citing Articles

Effect of long-term negative energy on appetite hormone levels in individuals with prediabetes and diabetes.

Alyar G, Umudum F, Yuce N, Akbas N Rev Assoc Med Bras (1992). 2025; 71(1):e20240897.

PMID: 39813443 PMC: 11723512. DOI: 10.1590/1806-9282.20240897.


Changes in Circulating Acylated Ghrelin and Neutrophil Elastase in Diabetic Retinopathy.

Trotta M, Gesualdo C, Russo M, Lepre C, Petrillo F, Vastarella M Medicina (Kaunas). 2024; 60(1).

PMID: 38256379 PMC: 10820226. DOI: 10.3390/medicina60010118.


Leu72Met Polymorphism in Ghrelin Gene: A Potential Risk Factor for Hypertension in Type 2 Diabetes Patients.

Buraczynska M, Golacki J, Zaluska W Diabetes Metab Syndr Obes. 2023; 16:557-564.

PMID: 36883139 PMC: 9985889. DOI: 10.2147/DMSO.S393373.

References
1.
Yuan F, Zhang Q, Dong H, Xiang X, Zhang W, Zhang Y . Effects of Des-acyl Ghrelin on Insulin Sensitivity and Macrophage Polarization in Adipose Tissue. J Transl Int Med. 2021; 9(2):84-97. PMC: 8386331. DOI: 10.2478/jtim-2021-0025. View

2.
Ward L . Bioelectrical impedance analysis for body composition assessment: reflections on accuracy, clinical utility, and standardisation. Eur J Clin Nutr. 2018; 73(2):194-199. DOI: 10.1038/s41430-018-0335-3. View

3.
Ozcan B, Neggers S, Miller A, Yang H, Lucaites V, Abribat T . Does des-acyl ghrelin improve glycemic control in obese diabetic subjects by decreasing acylated ghrelin levels?. Eur J Endocrinol. 2013; 170(6):799-807. DOI: 10.1530/EJE-13-0347. View

4.
Perna S, Spadaccini D, Gasparri C, Peroni G, Infantino V, Iannello G . Association between des-acyl ghrelin at fasting and predictive index of muscle derangement, metabolic markers and eating disorders: a cross-sectional study in overweight and obese adults. Nutr Neurosci. 2020; 25(2):336-342. DOI: 10.1080/1028415X.2020.1752997. View

5.
Grundy S . Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 2006; 47(6):1093-100. DOI: 10.1016/j.jacc.2005.11.046. View